

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6135722

|   |                              |
|---|------------------------------|
| <b>SUBMISSION TYPE:</b>   | NEW ASSIGNMENT               |
| <b>NATURE OF CONVEYANCE:</b>  | ASSIGNMENT                   |
| <b>CONVEYING PARTY DATA</b>   |                              |
| <b>Name</b>   | <b>Execution Date</b>        |
| INSPIRION DELIVERY SERVICES, LLC  | 04/30/2020                   |
| <b>RECEIVING PARTY DATA</b>   |                              |
| <b>Name:</b>  | OHEMO LIFE SCIENCES INC      |
| <b>Street Address:</b>  | CARR. 198 KM # 100           |
| <b>Internal Address:</b>  | JUNCOS INDUSTRIAL PARK       |
| <b>City:</b>  | JUNCOS                       |
| <b>State/Country:</b>   | PUERTO RICO                  |
| <b>Postal Code:</b>   | 00777-3873                   |
| <b>PROPERTY NUMBERS Total: 1</b>  |                              |
| <b>Property Type</b>  | <b>Number</b>                |
| <b>Application Number:</b>  | 13408076                     |
| <b>CORRESPONDENCE DATA</b>  |                              |
| <b>Fax Number:</b>  |                              |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> |                              |
| <b>Phone:</b>   | 703-548-3569                 |
| <b>Email:</b>   | wbeaumont@juneaumitchell.com |
| <b>Correspondent Name:</b>  | WILLIAM E. BEAUMONT          |
| <b>Address Line 1:</b>  | 1727 KING ST.                |
| <b>Address Line 2:</b>  | SUITE 300                    |
| <b>Address Line 4:</b>  | ALEXANDRIA, VIRGINIA 22314   |
| <b>ATTORNEY DOCKET NUMBER:</b>  | OHEMO-13408076               |
| <b>NAME OF SUBMITTER:</b>   | WILLIAM E. BEAUMONT          |
| <b>SIGNATURE:</b>   | /William E. Beaumont/        |
| <b>DATE SIGNED:</b>   | 06/03/2020                   |
| <b>Total Attachments: 16</b>  |                              |
| source=US_Assignment_AOP_2#page1.tif  |                              |
| source=US_Assignment_AOP_2#page2.tif  |                              |
| source=US_Assignment_AOP_2#page3.tif  |                              |
| source=US_Assignment_AOP_2#page4.tif  |                              |

source=US\_Assignment\_AOP\_2#page5.tif  
source=US\_Assignment\_AOP\_2#page6.tif  
source=US\_Assignment\_AOP\_2#page7.tif  
source=US\_Assignment\_AOP\_2#page8.tif  
source=US\_Assignment\_AOP\_2#page9.tif  
source=US\_Assignment\_AOP\_2#page10.tif  
source=US\_Assignment\_AOP\_2#page11.tif  
source=US\_Assignment\_AOP\_2#page12.tif  
source=US\_Assignment\_AOP\_2#page13.tif  
source=US\_Assignment\_AOP\_2#page14.tif  
source=US\_Assignment\_AOP\_2#page15.tif  
source=US\_Assignment\_AOP\_2#page16.tif

**ASSIGNMENT**

FOR GOOD AND VALUABLE CONSIDERATION GIVEN TO:

**INSPIRION DELIVERY SCIENCES, LLC**

100 Southgate Parkway  
Suite 100  
Morristown, New Jersey 07960

hereinafter referred to as **ASSIGNORS**, who were the owners of the entire, exclusive right, title and interest in the patents listed in Exhibit A of the Assignment of Patents of April 30, 2020, in the United States, and elsewhere,

have filed a patent entitled:

**ABUSE RESISTANT DRUGS, METHOD OF USE AND METHOD OF MAKING**

identified as

USSN 13/408,076

and whereas,

**OHEMO LIFE SCIENCES INC.**

Carr. 198 km 14.7 # 100  
Juncos Industrial Park, Juncos, Puerto Rico  
Juncos Puerto Rico 00777-3873  
Puerto Rico

which is a

**CORPORATION**

organized and existing under the laws of

**PUERTO RICO**

hereinafter referred to as the ASSIGNEE, has acquired the entire and exclusive right to all U.S. patents and patent applications from INSPIRION DELIVERY SCIENCES, LLC, by virtue of the ASSIGNMENT OF PATENTS agreement of

April 30, 2020, and elsewhere in the world as specified; and further, OHEMO LIFE SCIENCES INC. has acquired the right, title and interest in the listed U.S. patents and patent applications to file and prosecute any divisional, continuation, reissue, reexamination or requests for extended examination as desired by virtue of right as recognized in this agreement.

NOW THIS WITNESSETH that inasmuch as this ASSIGNMENT recognizes ASSIGNEE to be in exclusive possession and ownership of all rights pertaining to the listed U.S. patents and patent applications, and in the same position as ASSIGNOR if this ASSIGNMENT had not occurred, let it be known that in view of valuable consideration set forth in the Assignment of Patents of April 30, 2020, this ASSIGNMENT will be understood to hereby recognize all rights to the listed U.S. patents and patent applications belonging to ASSIGNEE, OHEMO LIFE SCIENCES INC., their assigns and legal representatives. The exclusive rights conferred grant the right to claim priority to any existing U.S. patent and/or patent application in any subsequent application filed by ASSIGNEE. ASSIGNEE thus enjoys all rights and privileges enjoyed by ASSIGNOR, and in as ample and beneficial of manner had this Assignment never been made, including the right and standing to bring and/or defend law suits having anything to do with the listed patents and patent applications in Exhibit A of the Assignment of Patents of April 30, 2020, including, but not limited to legal actions pertaining to patent infringement, validity and declaratory judgment.

FOR ASSIGNEE: OHEMO LIFE SCIENCES INC.

Name: Arthur M. Deboeck

Signature: Arthur M. Deboeck

Date: May 27, 20

Title: President

**ASSIGNMENT OF PATENTS**

**THIS ASSIGNMENT** ("Assignment") is dated as of April 30, 2020 (the "Closing Date") and entered into by and between **INSPIRION DELIVERY SCIENCES, LLC**, a Delaware limited liability company ("Seller"), and **OHEMO LIFE SCIENCES INC.**, a Puerto Rican corporation ("Purchaser").

**RECITALS**

A. Seller and Purchaser are also parties to that certain Asset Purchase Agreement dated as of March 31, 2020 (the "Purchase Agreement"), which among other things provides for the sale and transfer of the patents, patent applications and other patent rights specified in Exhibit A attached hereto (the "Patents"). Defined terms which are used but not defined in this Assignment shall have the meanings given to them in the Purchase Agreement.

B. The Purchase Agreement requires the execution and delivery of this Assignment by the parties hereto as of the Closing Date.

**AGREEMENT**

**NOW, THEREFORE**, in consideration of the premises and the mutual promises of the parties herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties intending to be legally bound hereby agree as follows:

1. Seller hereby sells, assigns, transfers, conveys and delivers to Purchaser all right, title and interest of Seller in and to the Patents.
2. Seller, as the registered holder of the Patents, hereby authorizes and requests the United States and foreign patent offices to transfer ownership of the Patents to Purchaser.
3. Purchaser hereby accepts such sale, assignment, transfer and conveyance of the Patents.
4. This Assignment (i) is binding on Seller, its successors and assigns, and will inure to the benefit of Purchaser, its successors and assigns, (ii) shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflict of laws principles thereof, (iii) shall be subject to the provisions of the Purchase Agreement, and (iv) may be executed in counterparts, each of which is an original and both of which, taken together, constitute a single instrument.

*[Remainder of this page left blank intentionally]*



IN WITNESS WHEREOF, the parties have caused their duly authorized officers to execute this Assignment as of the Closing Date.

**SELLER:**

**INSPIRION DELIVERY SCIENCES, LLC**

By: \_\_\_\_\_

Name: Derek C. Abbott, solely in his capacity as  
Liquidating Trustee of Inspirion Delivery  
Sciences, LLC and not individually

Title: Liquidating Trustee

**PURCHASER:**

**OHEMO LIFE SCIENCES INC.**

By: \_\_\_\_\_

Name: Arthur M. Deboeck

Title: President

13700974.2

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT ("Assignment") is dated as of April 30, 2020 (the "Closing Date") and entered into by and between INSPIRION DELIVERY SCIENCES, LLC, a Delaware limited liability company ("Seller"), and OHEMO LIFE SCIENCES INC., a Puerto Rican corporation ("Purchaser").

RECITALS

A. Seller and Purchaser are also parties to that certain Asset Purchase Agreement dated as of March 31, 2020 (the "Purchase Agreement"), which among other things provides for the sale and transfer of the patents, patent applications and other patent rights specified in Exhibit A attached hereto (the "Patents"). Defined terms which are used but not defined in this Assignment shall have the meanings given to them in the Purchase Agreement.

B. The Purchase Agreement requires the execution and delivery of this Assignment by the parties hereto as of the Closing Date.

AGREEMENT

NOW, THEREFORE, in consideration of the premises and the mutual promises of the parties herein contained, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties intending to be legally bound hereby agree as follows:


1. Seller hereby sells, assigns, transfers, conveys and delivers to Purchaser all right, title and interest of Seller in and to the Patents.
2. Seller, as the registered holder of the Patents, hereby authorizes and requests the United States and foreign patent offices to transfer ownership of the Patents to Purchaser.
3. Purchaser hereby accepts such sale, assignment, transfer and conveyance of the Patents.
4. This Assignment (i) is binding on Seller, its successors and assigns, and will inure to the benefit of Purchaser, its successors and assigns, (ii) shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflict of laws principles thereof, (iii) shall be subject to the provisions of the Purchase Agreement, and (iv) may be executed in counterparts, each of which is an original and both of which, taken together, constitute a single instrument.

*[Remainder of this page left blank intentionally]*

**IN WITNESS WHEREOF**, the parties have caused their duly authorized officers to execute this Assignment as of the Closing Date.

**SELLER:**

**INSPIRION DELIVERY SCIENCES, LLC**

By: 

Name: Derek C. Abbott, solely in his capacity as  
Liquidating Trustee of Inspirion Delivery  
Sciences, LLC and not individually

Title: Liquidating Trustee

**PURCHASER:**

**OHEMO LIFE SCIENCES INC.**

By: \_\_\_\_\_

Name: Arthur M. Deboeck

Title: President

13700974.2

This Assignment refers to USSN 13/408,076 which is listed as number # 2  
in attached Exhibit A of the Assignment of Patents

## EXHIBIT A: PATENTS

For clarity, the "Patents" shall include the following patents, patent applications and other patent listed in the following tables.

Note: The information in this EXHIBIT A is included from a list prepared in August 2016, and has not been updated to the Closing Date. This EXHIBIT A provides a non-exclusive listing of patents and patent applications included in the Intellectual Property included within the Acquired Assets. Other patents and patent applications may also apply and shall be included in the Intellectual Property included within the Acquired Assets.

### **Pending Foreign Applications**

*[Remainder of this page left blank intentionally]*

| Application #<br>(AF Ref #)                         | Title  | Subject Matter  | Filing Date           | Priority Information  | Examiner            | Status  |
|---|--|---|-----------------------|---|---------------------|---------|
| 1<br>12/680,701<br>(US 20110002965)<br>030713.00011 | Abuse Resistant<br>Drugs, Method of<br>Use and Method<br>of Making   | Original claims of PCT, minus<br>allowed claims issued in US<br>7,955,619   | September<br>16, 2010 | National stage of PCT/US08/72914, filed<br>8/12/08, which claims priority to USSN<br>60/955,584, filed 8/13/07  | Lisbeth<br>Robinson | Pending |
| 2<br>13/408,076<br>(US 20120164289)<br>030713.00026 | Abuse Resistant<br>Drugs, Method of<br>Use and Method<br>of Making   | Independent claim recites<br>limitations of original claims 1, 2,<br>and 16 of PCT (barrier, diffusion,<br>expansion layer, and barrier-<br>diffusion bond is substantially<br>preserved) | February<br>29, 2012  | Continuation of USSN 12/680,701, which<br>is national stage of PCT/US08/72914,<br>filed 8/12/08, which claims priority to<br>USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 3<br>13/040,775<br>(US 20110156970)<br>030713.00018 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Oxycodone,<br>Method of Use<br>and Method of<br>Making | ER oxycodone  | March 4,<br>2011      | Continuation of USSN 12/680,701, which<br>is national stage of PCT/US08/72914,<br>filed 8/12/08, which claims priority to<br>USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 4<br>13/408,068<br>(US 20120156277)<br>030713.00025 | Abuse Resistant<br>Drugs, Method of<br>Use and Method<br>of Making   | IR oxycodone  | February<br>29, 2012  | Continuation of USSN 12/680,701, which<br>is national stage of PCT/US08/72914,<br>filed 8/12/08, which claims priority to<br>USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 5<br>13/041,024<br>(US 20110159089)<br>030713.00019 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Morphine, Method<br>of Use and<br>Method of Making     | ER morphine   | March 4,<br>2011      | Continuation of USSN 12/680,701, which<br>is national stage of PCT/US08/72914,<br>filed 8/12/08, which claims priority to<br>USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |

|    |  |   |                           |                  |  |                     |         |
|----|--|---|---------------------------|------------------|--|---------------------|---------|
| 6  | 13/040,979<br>(US 20110150990)<br>030713,00020 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Hydrocodone,<br>Method of Use<br>and Method of<br>Making                | ER hydrocodone            | March 4,<br>2011 | Continuation of USSN 12/690,701, which is national stage of PCT/US09/72914, filed 8/12/08, which claims priority to USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 7  | 13/040,792<br>(US 20110150971)<br>030713,00021 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Oxymorphone,<br>Method of Use<br>and Method of<br>Making                | ER oxymorphone            | March 4,<br>2011 | Continuation of USSN 12/690,701, which is national stage of PCT/US09/72914, filed 8/12/08, which claims priority to USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 8  | 13/040,701<br>(US 20110150969)<br>030713,00022 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Hydromorphone,<br>Method of Use<br>and Method of<br>Making              | ER hydromorphone          | March 4,<br>2011 | Continuation of USSN 12/690,701, which is national stage of PCT/US09/72914, filed 8/12/08, which claims priority to USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 9  | 13/041,020<br>(US 20110150991)<br>030713,00023 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Morphine with<br>Oxycodone,<br>Method of Use<br>and Method of<br>Making | ER morphine/<br>oxycodone | March 4,<br>2011 | Continuation of USSN 12/690,701, which is national stage of PCT/US09/72914, filed 8/12/08, which claims priority to USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 10 | 13/040,953<br>(US 20110150990)<br>030713,00024 | Abuse Resistant<br>Drugs, Method of<br>Use, and Method<br>of Making   | IR morphine/<br>oxycodone | March 4,<br>2011 | Continuation of USSN 12/690,701, which is national stage of PCT/US09/72914, filed 8/12/08, which claims priority to USSN 60/955,584, filed 8/13/07 | Miriam<br>Levin     | Pending |

|    |  |   |  |                   |  |                                  |         |
|----|--|---|--|-------------------|--|----------------------------------|---------|
| 11 | 13/058,757<br>(US 20110184007)<br>030713.00017 | Pharmaceutical<br>Compositions<br>Configured to<br>Delay Dosage<br>Form Splitting | Composition<br>(Delaying Dosage Splitting)             | March 31,<br>2011 | National stage of PCT/US09/33919,<br>filed 2/12/09, which is a CIP of<br>PCT/US08/72914, filed 8/12/08,<br>which claims priority to USSN<br>609555584, filed 8/13/07 | Danah J.<br>Al-Awadi             | Pending |
| 12 | 14/218,782<br>(US 20140275150)<br>030713.00037 | Abuse Deterrent<br>Compositions and<br>Methods of Use                             | M6G/Coated/Ethanol:<br>Coated Formulation              | March 18,<br>2014 | Claims priority to USSN 61/799,096,<br>filed 3/15/13   | Brian<br>Gullidge                | Pending |
| 13 | 14/218,787<br>(US 20140271899)<br>030713.00038 | Abuse Deterrent<br>Compositions and<br>Methods of Use                             | M6G/Coated/Ethanol:<br>Ethanol Particle Size           | March 18,<br>2014 | Claims priority to USSN 61/799,096,<br>filed 3/15/13   | Audrea<br>Buckley                | Pending |
| 14 | 14/218,696<br>(US 20140275149)<br>030713.00039 | Abuse Deterrent<br>Compositions and<br>Methods of Use                             | M6G/Coated/Ethanol:<br>M6G: AUC Morphine               | March 18,<br>2014 | Claims priority to USSN 61/799,096,<br>filed 3/15/13   | Marcos<br>Sznajdman              | Pending |
| 15 | 14/218,791<br>(US 20140275038)<br>030713.00040 | Abuse Deterrent<br>Compositions and<br>Methods of Use                             | M6G/Coated/Ethanol:<br>M6G: AUC M6G                    | March 18,<br>2014 | Claims priority to USSN 61/799,096,<br>filed 3/15/13   | Angela C.<br>Brown-<br>Pettigrew | Pending |
| 16 | 14/218,792<br>(US 20140275039)<br>030713.00041 | Abuse Deterrent<br>Compositions and<br>Methods of Use                             | M6G/Coated/Ethanol:<br>M6G: AUC MOR + AUC M6G<br>(Sum) | March 18,<br>2014 | Claims priority to USSN 61/799,096,<br>filed 3/15/13   | Angela C.<br>Brown-<br>Pettigrew | Pending |

|    |   |  |                                     |                       |   |                     |         |
|----|---|--|-------------------------------------|-----------------------|---|---------------------|---------|
| 17 | 14274,384<br>(US 20140248344)<br>030713.00042 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Morphine, Method<br>of Use and<br>Method of Making         | ER morphine: Tier 1                 | May 9,<br>2014        | Continuation of USSN 13/041,024,<br>filed 3/4/11, which is a continuation<br>of USSN 12/680,701, which is<br>national stage of PCT/US08/72914,<br>filed 8/12/08, which claims priority to<br>USSN 60/955,584, filed 8/13/07 | Lisbeth<br>Robinson | Pending |
| 18 | 14274,319<br>(US 20140248343)<br>030713.00043 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Morphine, Method<br>of Use and<br>Method of Making         | ER morphine: Tier 2                 | May 9,<br>2014        | Continuation of USSN 13/041,024, filed<br>3/4/11, which is a continuation of USSN<br>12/680,701, which is national stage of<br>PCT/US08/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Lisbeth<br>Robinson | Pending |
| 19 | 14485,425<br>(US 20150005334)<br>030713.00044 | Abuse Deterrent<br>Compositions and<br>Methods of Use  | M6S/Coated/Ethanol: Sticking<br>CIP | September<br>12, 2014 | Continuation-in-part of USSN<br>14/216,782, filed on 3/18/14, which<br>claims priority to USSN 6/1799,096, filed<br>on March 15, 2013   | Brian<br>Gillpedge  | Pending |
| 20 | 14485,334<br>(US 20140377352)<br>030713.00045 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Morphine, Method<br>of Use, and<br>Method of Making        | ER morphine: method claims          | September<br>12, 2014 | Continuation of USSN 13/041,024, filed<br>3/4/11, which is a continuation of USSN<br>12/680,701, which is national stage of<br>PCT/US08/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Lisbeth<br>Robinson | Pending |
| 21 | 14486,433<br>030713.00036                     | Orally<br>Administerable<br>Compositions and<br>Methods of<br>Deterring Abuse<br>by Intranasal<br>Administration | US: Stefan Bulking                  | September<br>15, 2014 | None  | Kendra<br>Carter    | Pending |

|    |  |   |                    |                     |   |                 |         |
|----|--|---|--------------------|---------------------|---|-----------------|---------|
| 22 | 14/536,332<br>(US 2015064247)<br>030713.00047  | Abuse Resistant<br>Forms of<br>Immediate<br>Release<br>Hydrocodone,<br>Method of Use<br>and Method of<br>Making   | IR hydrocodone     | November<br>7, 2014 | Continuation of USSN 13/040,953, filed<br>on 3/4/11, which is a continuation of<br>USSN 12/680,701, filed on 9/16/10,<br>which is national stage of<br>PCT/US09/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Miriam<br>Levin | Pending |
| 23 | 14/536,391<br>(US 2015064245)<br>030713.00048  | Abuse Resistant<br>Forms of<br>Immediate<br>Release<br>Hydromorphone,<br>Method of Use<br>and Method of<br>Making | IR hydromorphone   | November<br>7, 2014 | Continuation of USSN 13/040,953, filed<br>on 3/4/11, which is a continuation of<br>USSN 12/680,701, filed on 9/16/10,<br>which is national stage of<br>PCT/US09/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Miriam<br>Levin | Pending |
| 24 | 14/536,459<br>(US 20150071996)<br>030713.00049 | Abuse Resistant<br>Forms of<br>Immediate<br>Release<br>Oxymorphone,<br>Method of Use<br>and Method of<br>Making   | IR oxymorphone     | November<br>7, 2014 | Continuation of USSN 13/040,953, filed<br>on 3/4/11, which is a continuation of<br>USSN 12/680,701, filed on 9/16/10,<br>which is national stage of<br>PCT/US09/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Miriam<br>Levin | Pending |
| 25 | 14/536,357<br>(US 20150071995)<br>030713.00050 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Hydrocodone,<br>Method of Use<br>and Method of<br>Making    | ER hydrocodone 2   | November<br>7, 2014 | Continuation of USSN 13/040,953, filed<br>on 3/4/11, which is a continuation of<br>USSN 12/680,701, filed on 9/16/10,<br>which is national stage of<br>PCT/US09/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Miriam<br>Levin | Pending |
| 26 | 14/536,396<br>(US 20150064248)<br>030713.00051 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Hydromorphone,<br>Method of Use<br>and Method of<br>Making  | ER hydromorphone 2 | November<br>7, 2014 | Continuation of USSN 13/040,953, filed<br>on 3/4/11, which is a continuation of<br>USSN 12/680,701, filed on 9/16/10,<br>which is national stage of<br>PCT/US09/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584, filed<br>8/13/07 | Miriam<br>Levin | Pending |

|    |  |  |                  |                       |  |                       |           |
|----|--|--|------------------|-----------------------|--|-----------------------|-----------|
| 27 | 14/536,478<br>(US 20150064246)<br>030713.00052 | Abuse Resistant<br>Forms of<br>Extended<br>Release<br>Oxymorphone,<br>Method of Use<br>and Method of<br>Making | ER oxymorphone 2 | November<br>7, 2014   | Continuation of USSN 13/040,953, filed<br>on 3/4/11, which is a continuation of<br>USSN 12/680,701, filed on 9/16/10,<br>which is national stage of<br>PCT/US08/72914, filed 8/12/08, which<br>claims priority to USSN 60/955,584 filed<br>8/13/07 | Miriam<br>Levin       | Pending   |
| 28 | 14/494,148                                     | Abuse Resistant<br>Forms of<br>Immediate<br>Release<br>Oxycodone,<br>Method of Use<br>and Method of<br>Making  |                  | September<br>23, 2014 | Continuation of U.S. 13/403,088, filed on<br>2/29/2012.  | Lisbeth C<br>Robinson | Abandoned |

Issued Patents

| Country | Patent No/<br>Application No.  | Title  | Filing Date/<br>Issue Date                  | Subject Matter           | AF<br>Reference |
|---------|--|--|---|--------------------------|-----------------|
| US      | U.S. Patent No. 7,955,819<br>(U.S. Patent Application No.<br>12/956,819) | Abuse Resistant Drugs, Method of Use and<br>Method of Making | Filed:<br>11/19/2010<br>Issued:<br>6/7/2011 | Composition<br>(general) | 030713.00013    |

*(Handwritten mark)*

Other Patents

| Country | Patent No/<br>Application No.  | Title   | Filing Date/<br>Issue Date  | Subject<br>Matter | AF<br>Reference |
|---------|--|---|---|-------------------|-----------------|
| 1       | WO<br>2014145195 A1<br>(published)<br>PCT/US2014/029917<br>(application) | An oral pharmaceutical composition in unit dosage form comprising: (1) a first portion comprising: an active ingredient and a pH-dependent component, and (2) a second portion comprising a pH-raising agent is provided. | Filed:<br>3/15/14<br>Issued:<br>9/18/2014                           |                   |                 |
| 2*      | US<br>20110245967<br>(publication)<br>12/755,014<br>(application)        | SECURE METHOD FOR DELIVERING REGULATED ITEMS INCLUDING DRUGS TO A PATIENT   | Application<br>Date<br>4/6/2010<br>Publication<br>Date<br>10/6/2011 |                   |                 |

\* Patent 2 has been abandoned.

Dual Use Patents

| Country | Patent appl. or<br>pub #                                    | Patent title   | Assignors       | Status    |
|---------|---|--|-----------------|-----------|
| CA      | 2906915<br>(application)                                    | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT COMPONENT AND PH-RAISING AGENT                   | Difalco<br>Shah | Pending   |
| EP      | 2968178 A1<br>(publication)<br>14764019.7<br>(application)  | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT COMPONENT AND PH-RAISING AGENT                   | Difalco<br>Shah | Published |
| US      | 20150017240<br>(publication)<br>14/498,865<br>(application) | PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT COMPONENT AND PH-RAISING AGENT                   | Difalco<br>Shah | Pending   |
| US      | 61/799,096<br>(application)                                 | ABUSE RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING A PH-DEPENDENT AGENT AND A PH-INDEPENDENT AGENT | Difalco<br>Shah | Expired   |

\*\*\*\*\*